Home > SureNano Science Ltd. SURNF

Tag: SureNano Science Ltd. SURNF

ThursdayMay 21, 2026 12:52 pm

QualityStocksNewsBreaks – Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments,” a recent article reads. “Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic.…

Continue Reading

FridayMay 15, 2026 10:30 am

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability. To view the full press release, visit https://ibn.fm/wsiDy About SureNano Science Ltd. SureNano Science Ltd. (CSE:…

Continue Reading

WednesdayMay 13, 2026 9:35 am

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in BioMedWire editorial coverage examining the rapid growth of the GLP-1 market, with the company highlighted for its subsidiary GlucaPharm Inc. and its development of GEP-44, a patented triple agonist peptide licensed from Syracuse University. The editorial notes that GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, positioning SureNano as an emerging microcap participant seeking to address limitations of first-generation GLP-1 therapies, including efficacy, tolerability and delivery flexibility. The coverage also…

Continue Reading

TuesdayMay 12, 2026 9:00 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)and may include a paid advertisement. SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies. The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats. SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials. The company provides exposure to the expanding GLP-1 and obesity treatment markets, which are…

Continue Reading

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The…

Continue Reading

FridayApr 24, 2026 9:30 am

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances GEP-44 Toward IND-Enabling Studies, Expands Investor Outreach

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44, to be conducted with LabCorp, aimed at supporting future Phase I clinical trials. The studies are designed to assess safety, dosing parameters and biomarkers across multiple species as the company advances its GLP-1 agonist peptide targeting Type II diabetes and obesity. The company also outlined expanded investor outreach initiatives, including a strategic agreement with Investor Brand Network (IBN)…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

QualityStocks is powered by IBNAi

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .